Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

PHVS

Pharvaris NV (PHVS)

Pharvaris NV
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:PHVS
일자시간출처헤드라인심볼기업
2024/12/0306:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
2024/11/1406:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
2024/11/1406:10GlobeNewswire Inc.Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business UpdatesNASDAQ:PHVSPharvaris NV
2024/11/1220:50GlobeNewswire Inc.Pharvaris to Participate in the Guggenheim Healthcare Innovation ConferenceNASDAQ:PHVSPharvaris NV
2024/11/0105:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
2024/10/2505:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
2024/10/2421:00GlobeNewswire Inc.Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific MeetingNASDAQ:PHVSPharvaris NV
2024/10/1619:50GlobeNewswire Inc.Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific MeetingsNASDAQ:PHVSPharvaris NV
2024/10/1519:50GlobeNewswire Inc.Pharvaris to Host Virtual Investor Event on October 23, 2024NASDAQ:PHVSPharvaris NV
2024/10/0319:50GlobeNewswire Inc.Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership WorkshopNASDAQ:PHVSPharvaris NV
2024/09/2519:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
2024/09/2319:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
2024/09/2105:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
2024/09/2007:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
2024/09/2007:44Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
2024/09/2005:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
2024/09/1705:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
2024/09/0519:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
2024/09/0519:50GlobeNewswire Inc.Pharvaris Provides Business Update and Expands Development Program for DeucrictibantNASDAQ:PHVSPharvaris NV
2024/09/0519:49GlobeNewswire Inc.Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024NASDAQ:PHVSPharvaris NV
2024/09/0519:48GlobeNewswire Inc.Pharvaris Presents Data at the Bradykinin Symposium 2024NASDAQ:PHVSPharvaris NV
2024/08/2819:50GlobeNewswire Inc.Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin SymposiumNASDAQ:PHVSPharvaris NV
2024/08/1419:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
2024/08/1419:50GlobeNewswire Inc.Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
2024/06/1119:52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
2024/06/1119:50GlobeNewswire Inc.Pharvaris Announces Annual Meeting of ShareholdersNASDAQ:PHVSPharvaris NV
2024/06/0505:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
2024/06/0419:50GlobeNewswire Inc.Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent CongressesNASDAQ:PHVSPharvaris NV
2024/05/2506:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
2024/05/2306:54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
 검색 관련기사 보기:NASDAQ:PHVS